key: cord-0802506-jklargqa authors: Khan, Taushif; Rahman, Mahbuba; Ali, Fatima Al; Huang, Susie S. Y.; Ata, Manar; Zhang, Qian; Bastard, Paul; Liu, Zhiyong; Jouanguy, Emmanuelle; Béziat, Vivien; Cobat, Aurélie; Nasrallah, Gheyath K.; Yassine, Hadi; Smatti, Maria; Sayeed, Amira; Vandernoot, Isabelle; Goffard, Jean-Christophe; Smits, Guillaume; Migeotte, Isabelle; Haerynck, Filomeen; Meyts, Isabelle; Abel, Laurent; Casanova, Jean-Laurent; Hasan, Mohammad R.; Marr, Nico title: Distinct antibody repertoires against endemic human coronaviruses in children and adults date: 2020-09-24 journal: bioRxiv DOI: 10.1101/2020.06.21.163394 sha: 9ed4c94b44a86c9544e688854eac54bc0e9cfc75 doc_id: 802506 cord_uid: jklargqa Four endemic human coronaviruses (HCoVs) are commonly associated with acute respiratory infection in humans. B cell responses to these “common cold” viruses remain incompletely understood. Here we report a comprehensive analysis of CoV-specific antibody repertoires in 231 children and 1168 adults using phage-immunoprecipitation sequencing. Seroprevalence of antibodies to endemic HCoVs ranged between ~4 and 27% depending on the species and cohort. We identified at least 136 novel linear B cell epitopes. Antibody repertoires against endemic HCoVs were qualitatively different between children and adults in that anti-HCoV IgG specificities more frequently found among children targeted functionally important and structurally conserved regions of the spike, nucleocapsid and matrix proteins. Moreover, antibody specificities targeting the highly conserved fusion peptide region and S2’ cleavage site of the spike protein were broadly cross-reactive with peptides of epidemic human and non-human coronaviruses. In contrast, an acidic tandem repeat in the N-terminal region of the Nsp3 subdomain of the HCoV-HKU1 polyprotein was the predominant target of antibody responses in adult donors. Our findings shed light on the dominant species-specific and pan-CoV target sites of human antibody responses to coronavirus infection, thereby providing important insights for the development of prophylactic or therapeutic monoclonal antibodies and vaccine design. susceptible to infection with epidemic CoVs and once infected, they are less likely to 93 experience severe outcomes compared to adults, although this important association and the 94 underlying reasons remain poorly understood [12, 18, 20, 21] . Importantly, it remains unclear 95 to what extent pre-existing immunity from past infections with endemic HCoVs provides 96 some degree of cross-protection and affects clinical outcomes of infection with the epidemic 97 SARS-CoV-2 or MERS-CoV. Our overall understanding of the immunity induced by natural 98 infection with endemic HCoVs remains very limited. Serological studies have shown some 99 degree of cross-reactive antibodies in patients with past CoV infections but many of these 100 studies were limited in sample size and often focused on specific viral antigens only [22] [23] [24] [25] . 101 Depending on their binding affinity and specificities, such cross-reactive antibodies could 102 either have no effect on clinical outcomes, may provide protection from severe disease to 103 some degree, or may lead to antibody-dependent enhancement of disease-the latter can be 104 a major obstacle in vaccine development [26] . Interestingly, two recent studies from 105 independent groups have shown that a considerable proportion of individuals without a 106 history of SARS-CoV-2 infection have SARS-CoV-2-reactive T cells, which suggests that cross-107 reactive T cell subsets originating from past infections by endemic HCoVs may play a role in 108 the clinical course of infection with the phylogenetically related epidemic CoVs [27, 28] . A 109 systematic assessment to elucidate the immunodominant B cell antigen determinants of 110 endemic HCoVs has not been done. We hypothesized that a fraction of the general population 111 also have antibodies generated during past encounters with 'common cold' coronaviruses 112 that cross-react with proteins of epidemic CoVs. This may affect the dynamics of sporadic 113 MERS outbreaks that mostly occur in the Middle East, and the current COVID-19 pandemic. 114 To gain a deeper insight into human antibody responses to endemic HCoVs, we performed 116 phage-immunoprecipitation sequencing (PhIP-Seq) [29-31] on previously collected serum or 117 plasma samples obtained from a total of 1431 human subjects from three different cohorts. Table S1 ). Of note, we utilized an expanded version of the VirScan phage 136 library [33, 34] , which also encompassed peptides from a number of proteins of human 137 epidemic and non-human CoV isolates, including MERS-CoV, SARS-CoV, as well as bat, bovine, 138 porcine and feline isolates belonging to the alpha-and betacoronavirus genera, albeit with 139 varying coverage of the viral peptidomes owing to the limitation in available sequence data 140 for the latter isolates in UniProt (Supplementary Table S1 ). SARS-CoV-2 peptides were not 141 included in the VirScan phage library used in our study. 142 We were able to obtain antibody repertoires for a total of 1399 individuals from the human 144 cohorts described above (Supplementary Table S2 ). Using stringent filter criteria (Methods), 7 we identified a total of 417 out of 2498 peptides and potential antigens from endemic HCoVs 146 with our screen that were significantly enriched in at least three of all 1399 analyzed 147 individuals. A total of 103 peptides from endemic HCoV were enriched in ³ 1% of the samples 148 and therefore considered to contain potentially immunodominant regions (Supplementary 149 Tables S3)] . 160 161 Next we assessed the seroprevalence of HCoV-229E, -NL63, -HKU1 and -OC43 in the three 162 cohorts separately. To do so, we imputed species score values as described earlier [31, 33, 163 36] by counting the significantly enriched peptides for a given HCoV species that share less 164 than 7 amino acids linear sequence identity. We considered an individual seropositive for any 165 of the endemic HCoVs if the number of non-homologous peptides enriched in a given sample 166 met our previously established species-specific cut-off value (Methods). Seroprevalence for 167 endemic HCoVs ranged from ~4% to ~27%, depending on the species and cohort ( Figure 1A) . 168 Interestingly, we found a marginal but significant negative association between age and 169 seroprevalence of HCoV-OC43 (b = -0.175) and -NL63 (b = -0.315) ( Figure 1B and 1D ), as well 170 as a marginal positive association between male gender and seroprevalence for any of the 171 endemic HCoVs (b £ 0.2) ( Figure 1C and 1D). The species score values (i.e. the antibody 172 repertoire breadth for each HCoV species) did not differ substantially between seropositive 173 individuals of our 3 cohorts (Supplementary Figure S3) . However, principal component 174 analysis revealed considerable qualitative differences in the antibody repertoires between 175 our cohorts and in particular between pediatric and adult subjects (Figure 2A ). For 8 comparison, we also performed the same analysis on enriched peptides from other common 177 respiratory viruses, including HRSV, HRV A, HRV B and influenza B virus. As expected, seroprevalence was considerably higher (68% to 99%) for HRSV, HRV A and HRV B, and 179 somewhat higher (29% to 47%) for influenza B virus (Supplementary Figure S4A) . However, 180 contrary to antiviral antibody responses to endemic HCoVs, we did not find considerable 181 variance in the antibody repertoires to other respiratory viruses when comparing age groups 182 and cohorts (Supplementary Figure S4B) . We also analyzed the enriched antigenic peptides 183 for each endemic HCoV species separately and found that most variance in the antibody 184 repertoires between cohorts and age groups were attributable to past infections with HCoV-185 HKU1 and -229E (Supplementary Figure S4C) . To determine the antibody specificities 186 responsible for most of the variance in the antiviral response to endemic HCoVs between 187 adults and children (i.e. to identify those peptides that were significantly more or less 188 frequently enriched when comparing adult and pediatric donors), we applied Fisher's exact 189 test and computed odds ratios for each of the significantly enriched peptides. We found that 190 antibody specificities in samples of pediatric study subjects predominantly targeted different 191 antigenic regions in the S protein (mean log odds ratio = 3.35 ± 2.12), the N protein (mean log 192 odds ratio = 2.21 ± 1.41) and diverse antigenic sites in pp1ab, whereas peptides encoding a 193 single linear B cell epitope of pp1ab (cluster 22) appeared to be the predominant target of 194 IgG antibodies among adult donors (mean log odds ratio = -4.7 ± 1.16 ) ( Figure 2B and Table 195 1). protein appeared to be less conserved between different species in the primary amino acid 212 sequence ( Figure 4C and 4D), both domains are structurally conserved in the regions that we 213 found to be immunodominant ( Figure 4E and 4F). We also found that antibodies in children 214 targeted more frequently the C-terminal domain of the M protein (Supplementary Figure S5C 215 and Table 1 ) and the small accessory Orf8 protein (also known as N2) of HCoV-HKU1 (Table 216 1). Although Orf8 and N share the same coding sequence in the viral RNA genome, the reading 217 frame is different and the amino acid sequences not homologous. On the contrary, antibody 218 specificities predominantly found in adults primarily targeted a region of the pp1ab that is Table S1 ) applying the same approach and stringent filter criteria as 228 described above, for peptides of endemic HCoVs. Indeed, we identified several S protein-and 229 N protein-derived peptides from epidemic CoVs or non-human isolates that were significantly 230 enriched in our PhIP-Seq assay, which share sequence similarity with peptides from HCoVs 231 ( Figure 5 ). As expected based on the results from multiple sequence alignments described 232 above, antibody specificities targeting the highly conserved amino acid motif 233 subjects, but also many (if not all) of the children aged 7 to 15 years that were assessed in our 313 study, have already experienced multiple infections with endemic HCoVs in their lifetime. 314 Therefore, our estimated seroprevalence rates likely reflect the complex dynamics between 315 rates of (re-)infection and waning humoral immunity over time. In agreement with this 316 notion, age was negatively associated with seroprevalence in our study, suggesting that the 317 duration of immunity in response to natural infection with endemic HCoVs and/or rates of re-318 infection reduce with increasing age. The dynamics of humoral immunity from past CoV 319 infections is best described in studies of MERS and SARS patients. Although limited in sample 320 size, these studies have shown that antibody titers in all previously infected individuals 321 decline relatively quickly to minimal detectable levels over a period of 2 to 3 years and that 322 patients who suffered from more severe disease had higher and longer-lasting total binding antibody titers and neutralizing titers [52] . There is also evidence that symptomatic COVID-324 19 patients mount robust antibody responses that wane very quickly over a period of 6 325 months [53] . However, the same study suggeted that SARS-CoV-2-specific memory B cells 326 may be sustained over a longer period of time [53] . Indeed, most acute virus infections induce 327 some level of protective and long-term immunity, albeit through a variety of mechanisms that 328 are not necessarily the same for each pathogen and may even differ between hosts due to a 329 variety of factors, including simultaneous viral coinfection [54, 55] . We also found a marginal 330 but significant positive association between seroprevalence of endemic HCoVs and male 331 gender, which is consistent with an earlier report by Gaunt et al. model to test for associations between the HCoV species-specific adjusted score values, 453 gender and age. We considered an association to be significant if the P-value was £ 0.001. We 454 examined the frequency distribution of enriched peptides among samples of the different age 455 groups (PED versus ABD + QBB) by estimating odds ratios (OR) and associated P-values using 456 Fisher's exact test. Peptides that satisfied both significance (P-value £ 0.005) and magnitude 457 criteria (|log(OR)| ³ log(2)) were considered to be differentially enriched. Positive log(OR) 458 values indicated more frequent peptide enrichment among pediatric study subjects, whereas 459 negative log(OR) values indicated more frequent peptide enrichment among adult subjects. Nodes marked with a black circle indicate peptides for which differential enrichment between 767 children and adults was statistically significant (P-value £ 0.005, Fisher's exact test) and odds 768 ratios were ³ 2. SR-rich, serine-and arginine-rich motive; IDR, intrinsically disordered region. 769 770 A New Virus Isolated from the Human Respiratory recovered patient remains stable while antibodies decay over time. medRxiv Increased Immune Response Variability during Simultaneous Viral 627 Coinfection Leads to Unpredictability in CD8 T Cell Immunity and Pathogenesis Two linear epitopes on the SARS-CoV-2 spike protein that elicit 630 neutralising antibodies in COVID-19 patients The SR-rich motif in SARS-CoV nucleocapsid protein is important for 633 virus replication The SARS-CoV nucleocapsid protein: a protein with 635 multifarious activities Structure, Function, and Evolution of Coronavirus Spike Proteins Furin cleavage of the SARS coronavirus spike 639 glycoprotein enhances cell-cell fusion but does not affect virion entry Human Coronavirus: Host-Pathogen Interaction Pre-existing yellow fever immunity impairs and modulates the 651 antibody response to tick-borne encephalitis vaccination. npj Vaccines Immune history profoundly affects broadly protective B cell 654 responses to influenza Currently available intravenous 657 immunoglobulin contains antibodies reacting against severe acute respiratory 658 syndrome coronavirus 2 antigens SARS-CoV-2 Antibody Avidity Responses in COVID-19 Patients and 660 Deployment of convalescent plasma for the prevention and 662 treatment of COVID-19 The convalescent sera option for containing COVID-664 Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2 Inborn errors of type I IFN immunity in patients with life-threatening The EMBL-EBI search and sequence analysis tools APIs in MAFFT multiple sequence alignment software version 7: 672 improvements in performance and usability Using EMBL-EBI Services via Web Interface and Programmatically 674 via Web Services IEDB-AR: immune epitope database-analysis resource in Proteolytic cleavage sites 709 of the S protein are marked with arrows. B, Overview of a multiple sequence alignment of 710 immunodominant peptides with the full-length protein sequences of various alpha The mean score (blue line) and standard deviations (shaded) for the residue-wise 712 prediction of linear B cell epitopes of aligned endemic HCoVs (bottom) Amino 718 acid sequences of previously predicted immunodominant linear SARS-CoV-2 B cell epitopes 719 [43] are highlighted in pink. For the BepiPred score (bottom), a score cutoff of 0.55 has been 720 marked with a dashed red line to indicate regions that are predicted to be potential B cell 721 epitopes. C-E, Selected regions of the multiple sequence alignment encompassing regions 1, 722 2 and 3 as shown in (B) The full sequence alignment is shown in Supplementary Figure S5A. F, Ribbon diagram of the SARS-CoV-2 S trimer with carbohydrate residues shown (top left) and monomer without 725 carbohydrate residues (middle) in the prefusion conformation 726 regions 1, 2 and 3 are shown enlarged. FP, fusion peptide; HR1 and HR2, heptad repeat 1 and 727 2. 728 of the aligned sequence. Peptides for which differential enrichment between children and 740 adults was statistically significant (P-value £ 0.005, Fisher's exact test) and odds ratios were Amino acid sequences of 743 previously predicted immunodominant SARS-CoV B cell epitopes [43] are highlighted in pink 744 color. For the BepiPred score (bottom), a score cutoff of 0.55 has been marked with a dashed 745 red line to indicate regions that are predicted to be potential B cell epitopes. C, D, Selected 746 regions of the multiple sequence alignment encompassing the N-terminal RNA-binding 747 domain (C) and C-terminal self-assembly domain (D). The full multiple sequence alignment is 748 shown in PDB: 5N4k, chain A) and that from SARS-CoV-2 (PDB: 750 6M3M, chain A) (root-mean-square deviation [rmsd] = 0.7 Ångström). F, Super-imposed 751 ribbon structure of the C-terminal self assembly domain of proteins from HCoV-NL63 (pdbId: 752 5EPW, chain A) and that of SARS-CoV-2 Predicted epitopes in peptides for which differential enrichment between children and adults 754 was statistically significant (P-value £ 0.005, Fisher's exact test) and odds ratios were ³ 2; # Predicted immunodominant epitopes